PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Abnova

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Abnova and Japan National Cancer Center File Patent on Ovarian Cancer Prognosis and Companion Diagnostic Biomarker for Personalized Therapy - Abnova Corporation and Japan National Cancer Center Research Institute have jointly filed an international patent covering a novel protein, Cystathionine gamma-Lyase, CTH, relating to ovarian cancer prognosis, companion diagnosis and therapy
Abnova and Japan National Cancer Center File Patent on Ovarian Cancer Prognosis and Companion Diagnostic Biomarker for Personalized Therapy

 

NewswireToday - /newswire/ - Neihu, Taiwan, 2010/09/20 - Abnova Corporation and Japan National Cancer Center Research Institute have jointly filed an international patent covering a novel protein, Cystathionine gamma-Lyase, CTH, relating to ovarian cancer prognosis, companion diagnosis and therapy.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This is the result of a collaborative work screening a large collection monoclonal antibodies on ovarian cancer tissue specimens, confirming protein biomarker with strongest statistical correlation to disease prognosis in both multiple and independent patient cohorts, and validating its utility as therapeutic target in vitro. With the advent of personalized medicine, biotech and pharmaceutical industries are mandated to develop more efficacious drugs based on protein phenotype diagnosis of the patient. The feasibility of this new paradigm can be seen in the commercial success of companion diagnostics such as HER2 protein marker for Herceptin® monoclonal antibody therapy and EGFR mutation for ERISSA chemotherapy. Leveraging the same paradigm, Abnova prepares to develop the CTH into a full-fledge, in vitro diagnostic (IVD) biomarker not only to identify the subset of ovarian cancer patients with poor prognosis but also provide a companion drug target for more effective personalized treatment. The timing of this IVD application is in line with Abnova’s scheduled ISO13485 completion this year as a prerequisite for diagnostic product development.

Ovarian cancer is the second most common gynecological cancer and fifth most common cause of cancer death in women. Ovarian cancer does not usually cause symptom until it has enlarged or spread. Hence, patients usually present with more advanced tumor stage at the time of diagnosis. At such, surgery is often needed to debulk the tumor followed by chemotherapy. Notably, overexpression of CTH protein in ovarian cancer tissue prior to drug therapy is significantly correlated with worse prognosis according to our study. The expression of CTH protein can be analyzed via a simple yet powerful immunohistochemical technique using a monoclonal antibody on formalin-fixed, paraffin-embedded tissue taken from patient at the time of biopsy or after surgery. Moreover, platinum-based chemotherapy such as carboplatin is invariably given to majority of patients as first-line treatment with an estimated $500M USD global market in an attempt to remove any remaining tumor after the surgery. However, platinum-based drug resistance is a serious problem which occurs in 70-80 percent of the ovarian cancer patients. We have observed that concurrent inhibition of CTH enzyme in CTH overexpressed tumor cell significantly augments the efficacy of platinum-based treatment. Additional experiments are underway to replicate the tumor cell results on animal model, as a predecessor for consideration and development of CTH targeted therapy in human. These combined findings and the utility of CTH as a biomarker for ovarian cancer will be published before end of this year. Abnova has also started to source potential drug inhibitor candidates of CTH which can be utilized in humans.

About Abnova

Abnova (abnova.com) is the world’s largest monoclonal antibody manufacturer. The system Abnova has developed is a unique combination of world-class technologies and management experience of the IT industry in Taiwan. By taking a genome-wide, approach to industrial-scale production, the company has vastly expanded the scope and availability of monoclonal antibodies which are the essential bio-tools for accelerating all facets of research and discovery in the biotech and pharmaceutical industries. Abnova intends to leverage its antibody capability to the creation and development of antibody integrated systems, point-of-care in vitro diagnostics (IVD), and fully human monoclonal antibody therapeutics for the treatment of infection and cancer.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Abnova

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Abnova and Japan National Cancer Center File Patent on Ovarian Cancer Prognosis and Companion Diagnostic Biomarker for Personalized Therapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Abnova.com 
+886 2-87511888 marketing[.]abnova.com.tw
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Abnova securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Abnova / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)